Chiome the latest Japanese bioventure to head to market
This article was originally published in Scrip
The Japanese bioventure Chiome Bioscience has received approval to list on the Mothers market of the Tokyo Stock Exchange on 20 December, at a price yet to be determined.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team.